WO2013177599A1 - Composition nutricosmétique - Google Patents

Composition nutricosmétique Download PDF

Info

Publication number
WO2013177599A1
WO2013177599A1 PCT/ZA2012/000036 ZA2012000036W WO2013177599A1 WO 2013177599 A1 WO2013177599 A1 WO 2013177599A1 ZA 2012000036 W ZA2012000036 W ZA 2012000036W WO 2013177599 A1 WO2013177599 A1 WO 2013177599A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mass
nutricosmetic
test
skin
Prior art date
Application number
PCT/ZA2012/000036
Other languages
English (en)
Inventor
Trevor Douglas BAILLIE
Jacobus Johannes VAN DER WESTHUIZEN
Original Assignee
Lunar Pharmaceuticals (Pty) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunar Pharmaceuticals (Pty) Ltd filed Critical Lunar Pharmaceuticals (Pty) Ltd
Priority to PCT/ZA2012/000036 priority Critical patent/WO2013177599A1/fr
Publication of WO2013177599A1 publication Critical patent/WO2013177599A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the invention relates to a nutricosmetic composition which when taken orally or topically reduces the appearance of wrinkles in the skin and makes the skin look younger and fresher.
  • Cosmeceuticals represent the marriage of cosmetics and pharmaceuticals. Examples of products typically labeled as cosmeceuticals include anti-aging creams and moisturizers. Cosmeceuticals are cosmetic products with biologically active ingredients purporting to have medical or drug-like benefits. Dermatological research suggests that the bioactive ingredients used in cosmeceuticals do indeed have benefits beyond the traditional moisturizer (e.g., Chen et al., 2005; Zettersten, Ghadially, Feingold, Crumrine, & Elias, 1997).
  • a nutricosmetic composition including at least: a stibenoid; a catechin; a benzoquinone; and a piperine or a derivative or extract thereof.
  • the stibenoid may be fraA7s-3,5,4 , -Trihydroxystilbene ) an analogue or an isomer thereof, or a mixture or blend of said analogues and isomers.
  • the catechin may be [(2 ?,3f?)-5,7-dihydroxy-2-(3 I 4,5-trihydroxyphenyl)chroman-3- yl]3,4,5-trihydroxybenzoate, an analogue or an isomer thereof, or a mixture or blend of said analogues and isomers.
  • the benzoquinone may be 2-[(2£,6E,10£, 4E,18£,22E,26E,30E,34E)- 3,7,11 ,15,19,23,27,31 ,35,39-decamethyltetraconta-2,6,10,14, 18,22,26,30,34,38- decaenyl]-5, 6-dimethoxy-3-methylcyclohexa-2,5-diene-1 ,4-dione, an analogue or an isomer thereof, or a mixture or blend of said analogues and isomers.
  • the piperine may be 1-[5-(1 ,3-benzodioxol- 5-yl)-1-oxo-2,4-pentadienyl]piperidine, an analogue or an isomer thereof, or a mixture or blend of said analogues and isomers.
  • the composition may include one or more fats, oils, and waxes.
  • the fats, oils, and waxes may be of biological origin.
  • the fats and oils may be of vegetable origin.
  • the waxes may be of arthropod origin.
  • the composition may include one or more phospholipids of plant or animal origin.
  • the phospholipids may be esters of a phosphatidic acid with choline.
  • the phospholipid may be lecithin.
  • the composition may include one or more excipients such as gelatine, C3O3H8, water, colourants, preservatives, flavourings, and the like. The choice of excipients is to some extent a choice based on the form, taste and smell of the nutricosmetic composition dosage form desired.
  • the nutricosmetic composition may be administered in the form of a liquid or gel capsule, such as that known as a softgel.
  • the nutricosmetic composition may have a composition as follows:
  • a softgel form having a wet mass of from 400 mg to 1500 mg per softgel unit, provided that sum of the selected mass% of the ingredients adds up to 100%.
  • the invention extends to the use of a composition of the invention in a nutricosmetic formulation administered orally, for the improved appearance of the skin of the person taking same.
  • the nutricosmetic composition when taken once daily as a soft gel having: approx. 20 mass% of trans-3, 5,4'-Trihydroxystilbene;
  • the Corneometer was calibrated with supplier calibration set.
  • the temperature and relative humidity were recorded during the time of the study.
  • test subjects An operator trained the test subjects in applying the test products evenly to the test sites, according to the test substance sequence. Subjects were verbally instructed on oral intake of the supplied test capsule.
  • the Corneometer was calibrated with supplier calibration set. The temperature and relative humidity were recorded during the time of the study.
  • the designated day readings were taken at three different test sites.
  • the corneometer probe was gently cleaned with a tissue between each reading.
  • the measurement of skin moisture is via capacitance using a CORNEOMETER 825. This measurement is based on the different dielectric constants of water (81 ) and other substances ( ⁇ 7). The measuring capacitor shows changes of capacitance according to the moisture content of the sample. (Courage and Khazaka Gmbh 2010).
  • Air humidity and room temperature will be controlled, as the higher the temperature and Humidity the higher the skin's moisture level (Report 1990).
  • An increase in the value indicates an increase in moisture content, where 0 indicates no moisture and 100 indicates water.
  • Results A Wilcoxon Signed Rank Sum Test was performed to compare the treated and the placebo sites at baseline (thus before application of test products) and no statistical significant difference was found between the two test sites on a 5% level of significance.
  • a Wilcoxon Signed Rank Sum Test was performed to determine the treatment effect by comparing the average values at day fourteen (D 4) of the treated and placebo sites and there was a statistical significance difference on a 5% level of significance. The average values for the treated sites were significantly bigger than the Placebo sites.
  • a t-Test was performed to determine the treatment effect by comparing the average values at day twenty-eight (D28) of the treated and placebo sites and there was no statistical significance difference on a 5% level of significance.
  • a t-Test was performed to determine the treatment effect by comparing the average values at day fifty-six (D56) of the treated and placebo sites and there was no statistical significance difference on a 5% level of significance.
  • test softgel group was effective in increasing the moisture level after fourteen days(D14) of consecutive use (one oral capsule) when compared to a placebo cell.
  • the objective of the study was to determine the Smoothness efficacy of a test product on the face of human subjects.
  • the designated left or right hand and matching side of the face was cleansed with a standard eye make-up remover and allowed to air dry for three minutes.
  • the temperature and relative humidity were recorded during the time of the study.
  • test sites were demarcated as per test sequence substance. Three (3) baseline readings were taken at the different test sites.
  • Subjects were restricted from using any topical products or any medication not approved by the study sponsor for the duration of the study. Subjects returned to the testing facility on days 14, 28, 56 respectively after baseline readings.
  • the temperature and relative humidity were recorded during the time of the study.
  • the designated day readings were taken at three different test sites.
  • the visioscan camera was gently cleaned with a tissue between each reading.
  • Results A Wilcoxon Signed Rank Sum Test was performed to compare the treated and the placebo sites at baseline (thus before application of test products) and no statistical significant difference was found between the two test sites on a 5% level of significance.
  • a Wilcoxon Signed Rank Sum Test was performed to determine the treatment effect by comparing the average values at day fourteen (D14) of the treated and placebo sites and there was a statistical significance difference on a 5% level of significance. The average values for the treated sites were significantly bigger than the Placebo sites.
  • a t-Test was performed to determine the treatment effect by comparing the average values at day twenty-eight (D28) of the treated and placebo sites and there was a statistical significance difference on a 5% level of significance. The average values for the treated sites were significantly bigger than the Placebo sites. A t-Test was performed to determine the treatment effect by comparing the average values at day fifty-six (D56) of the treated and placebo sites and there was no statistical significance difference on a 5% level of significance.
  • test softgel group was effective in increasing the smoothness level after fourteen (D14) and twenty-eight (D28) days of consecutive use (one oral capsule) when compared to a placebo cell.
  • the objective of the study was to determine the elasticity efficacy of a test product on the hands and face of human subjects.
  • Method Four groups of at least twenty (20) subjects between the ages of 18 and 68 were recruited.
  • the designated left or right hand and matching side of the face was cleansed with a standard eye make-up remover and allowed to air dry for three minutes.
  • the temperature and relative humidity were recorded during the time of the study.
  • test sites were demarcated as per test sequence substance. Three (3) baseline readings were taken at the different test sites.
  • Subjects returned to the testing facility on days 14, 28, 56 respectively after baseline readings. All Subjects were instructed to rest for twenty minutes before any testing was conducted.
  • the temperature and relative humidity were recorded during the time of the study.
  • the designated day readings were taken at three different test sites.
  • the cutometer probe was gently cleaned with a tissue between each reading.
  • Results A t-Test was performed to compare the treated and the placebo sites at baseline (thus before application of test products) and no statistical significant difference was found between the two test sites on a 5% level of significance.
  • a Wilcoxon Signed Rank Sum Test was performed to determine the treatment effect by comparing the day fourteen (D14-D0) values at of the treated and placebo sites and there was no statistical significance difference on a 5% level of significance.
  • a Wilcoxon Signed Rank Sum Test was performed to determine the treatment effect by comparing the day twenty-eight (D28-D0) values of the treated and placebo sites and there was no statistical significance difference on a 5% level of significance.
  • test softgel group was not effective in increasing the elasticity level after fourteen (D14), twenty-eight (D28) days and fifty-six days (D56) of consecutive use (one oral capsule) when compared to a placebo cell.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition nutricosmétique comprenant au moins un stilbénoïde, une catéchine, une benzoquinone et une pipérine, ou un dérivé, ou un extrait de ceux-ci. L'invention s'étend à un procédé d'amélioration de l'apparence de la peau d'une personne par l'administration d'une capsule molle de la composition décrite dans l'invention.
PCT/ZA2012/000036 2012-05-22 2012-05-22 Composition nutricosmétique WO2013177599A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/ZA2012/000036 WO2013177599A1 (fr) 2012-05-22 2012-05-22 Composition nutricosmétique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ZA2012/000036 WO2013177599A1 (fr) 2012-05-22 2012-05-22 Composition nutricosmétique

Publications (1)

Publication Number Publication Date
WO2013177599A1 true WO2013177599A1 (fr) 2013-11-28

Family

ID=46599029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2012/000036 WO2013177599A1 (fr) 2012-05-22 2012-05-22 Composition nutricosmétique

Country Status (1)

Country Link
WO (1) WO2013177599A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003307A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
WO2008134712A2 (fr) * 2007-04-30 2008-11-06 Living Proof, Inc. Utilisation d'inhibiteurs de la métalloprotéinase de la matrice pour les soins de la peau
WO2010118419A2 (fr) * 2009-04-10 2010-10-14 Haiyan Qi Nouveaux agents anti-vieillissement et leurs procédés d'identification
JP2011184429A (ja) * 2010-02-10 2011-09-22 Univ Of Tsukuba 低分子抗酸化剤及び高分子化環状ニトロキシドラジカル化合物を含む組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003307A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
WO2008134712A2 (fr) * 2007-04-30 2008-11-06 Living Proof, Inc. Utilisation d'inhibiteurs de la métalloprotéinase de la matrice pour les soins de la peau
WO2010118419A2 (fr) * 2009-04-10 2010-10-14 Haiyan Qi Nouveaux agents anti-vieillissement et leurs procédés d'identification
JP2011184429A (ja) * 2010-02-10 2011-09-22 Univ Of Tsukuba 低分子抗酸化剤及び高分子化環状ニトロキシドラジカル化合物を含む組成物

Similar Documents

Publication Publication Date Title
US11052032B2 (en) Peptide compositions and methods for ameliorating skin laxity and body contour
CN101820849B (zh) 局部施用性化妆品或药物组合物
EP3335693B1 (fr) Composition pour usage externe
CN106726784B (zh) 天然有机乳木果护甲膏及其制备方法
Bergera-Virassamynaïk et al. Evaluation of the Efficacy of an Ecobiological Dermo-Cosmetic Product to Help Manage and Prevent Relapses of Eyelid Atopic Dermatitis
KR101151008B1 (ko) 피탄트리올과 헥사미딘디이세치오네이트를 함유하는 여드름 개선용 화장료 조성물
WO2019025730A1 (fr) 1,4 :3,6 dianhydrohexitols pour hydrater la peau
Lønne et al. Composition characterization and clinical efficacy study of a salmon egg extract
US20140227204A1 (en) Skin compositions containing hydrocortisone
Leonardi et al. Application of a non-invasive method to study the moisturizinD effect of formulations containinD vitamins A or
CN112386655A (zh) 大白蝴蝶兰萃取物用于制备抗醣化与改善皮肤外观的组合物的用途
KR102036141B1 (ko) 이중캡슐공정을 이용한 콜레스테릭 액정을 함유하는 화장료 조성물
EP3443949A1 (fr) Émulsion imitant la peau
WO2013177599A1 (fr) Composition nutricosmétique
KR20180010743A (ko) 수박 과피 착즙액을 유효성분으로 함유하는 피부의 노화 방지용 화장료 조성물
Khan et al. Hippophae rhamnoides oil-in-water (O/W) emulsion improves barrier function in healthy human subjects
Yatsuhashi et al. Effects of oral supplementation with paprika xanthophylls on human skin moisture
JP2008169196A (ja) 皮膚外用剤
KR20080088735A (ko) 보습 복합물을 함유한 피부 보습용 화장료 조성물
CN115813826B (zh) 一种紧致抗皱组合物及其在化妆品中的应用
KR20160020038A (ko) 프랜지패니 오일 또는 프랜지패니 오일의 발효물을 포함하는 화장료 조성물
KR101597505B1 (ko) 감인, 속수자 및 영실 혼합 추출오일을 함유하는 민감성 피부 예방 또는 개선용 화장료 조성물
KR20140057040A (ko) 피페린계 화합물을 유효성분으로 포함하는 피부노화 개선용 조성물
KR101615900B1 (ko) 커큐마 잔소리자를 유효성분으로 함유하는 피부 노화 방지용 조성물
Matysiak et al. STUDIES ON THE FORMULATION AND FUNCTIONALITY OF AN INNOVATIVE LINE OF TOPICAL PRODUCTS FOR ATOPIC SKIN.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12741238

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12741238

Country of ref document: EP

Kind code of ref document: A1